Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript Summary
Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript Summary
Gross The following is a summary of the Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript:
以下是evolus公司（EOLS）2024年第三季度业绩会议呼叫记录摘要:
Financial Performance:
财务表现:
Evolus achieved a 33% increase in year-to-date revenue compared to 2023.
Q3 2024 net revenue was $61 million, up 22% from the previous year.
Gross margin for Q3 2024 was 68.9%, with an adjusted gross margin of 70.2%.
Non-GAAP operating loss in Q3 2024 was $6.7 million due to seasonally lower revenue.
与2023年相比，evolus的年度营业收入增长了33%。
2024年第三季度净营业收入为6100万美元，较去年同期增长22%。
2024年第三季度的毛利率为68.9%，调整后的毛利率为70.2%。
由于季节性营业收入较低，2024年第三季度的非GAAP运营亏损为670万美元。
Business Progress:
业务进展:
Launched Estyme in Europe and preparing for the US launch of Evolysse.
Added over 600 purchasing accounts in Q3, maintaining a reorder rate over 70%.
Launched Club Evolus, a subscription-based consumer membership program.
在欧洲推出了Estyme，并为美国上市evolysse做准备。
在第三季度新增了600多个采购账户，重新订购率保持在70%以上。
推出了Evolus俱乐部，一个基于订阅的消费会员计划。
Opportunities:
机会：
Expected revenue growth driven by neurotoxin business and new injectable HA gels beginning in 2025, targeting $700 million in net revenue by 2028.
Evolus is capitalizing on a total addressable market expected to grow from $6 billion now to approximately $10 billion by 2028.
预计由神经毒素业务和2025年开始的新注射式HA凝胶带来的收入增长，目标是到2028年达到70000万元的净收入。
Evolus正在利用预计从现在的60亿美元增长到2028年约100亿美元的总可寻址市场。
Risks:
风险：
Seasonal reduction in revenue typically seen in Q3 affects the financial results.
Possible impacts from the upcoming market entry of competitor Hugel.
第三季度通常出现的营业收入季节性减少会影响财务结果。
竞争对手Hugel即将进入市场可能会产生影响。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
